← All trials
NCT01490502
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2012
- Primary completion
- Mar 1, 2019
- Completion date
- Mar 1, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 172
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Johns Hopkins UniversityLead sponsor
- Johns Hopkins UniversityOverall official - principal investigator
- Oregon Health and Science UniversityCollaborator
- University of California, San FranciscoCollaborator
- University of PennsylvaniaCollaborator
- Yale UniversityCollaborator
- University of RochesterCollaborator
- Stanford UniversityCollaborator
- University of VirginiaCollaborator
- Columbia UniversityCollaborator
- University of MassachusettsCollaborator
- University of WashingtonCollaborator
- Anne Arundel Health System Research InstituteCollaborator
- Johns Hopkins UniversityReponsible party - principal investigator
- Washington University in St. LouisCollaborator
- Icahn School of Medicine at Mount SinaiCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.